ArticleNature immunology2022
Shared and distinct biological circuits in effector, memory and exhausted CD8
Open access · greenAbstract read
In one paragraph
Article in Nature immunology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 183 papers.
0numbers the graph read from it
0cells of the map it votes in
183citing papers in PubMed
18.2field-weighted citation impact, top 1% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
183 citing papers in PubMed, 234 citations in OpenAlex.
- A phase I/II trial of WT1-specific TCR gene therapy for patients with acute myeloid leukemia and active disease post-allogeneic hematopoietic cell transplantation: skewing towards NK-like phenotype impairs T cell function and persistence.Nature communications · 2025Trial
- Coupling of response biomarkers between tumor and peripheral blood in patients undergoing chemoimmunotherapy.Cell reports. Medicine · 2025Trial
- Combined JAK inhibition and PD-1 immunotherapy for non-small cell lung cancer patients.Science (New York, N.Y.) · 2024Trial
- Article
- Article
- Impaired regulation by purinergic signaling axis contributes to CD8+ T cell dysregulation in STAT3 gain of function.JCI insight · 2026Article
- In vivo effect of anti-PD-1 on HIV-specific CD8+T-cells in men with HIV.Nature communications · 2026Article
- The ADAP-TRIM21-ZEB2 axis regulates CD8iScience · 2026Article
- Both soluble and cell surface CD137 expressed by Foxp3+ CD4 T cells restrain autoimmune diabetes.The Journal of experimental medicine · 2026Article
- The transcription factor IRF8 drives tumor-specific exhaustion in CD8+ T cells.The Journal of experimental medicine · 2026Article
- CARM1-mediated hypoxanthine-enriched exosomes rewire inosine metabolism and impair CD8Cell death and differentiation · 2026Article
- GZMK-expressing tissue-resident memory CD8+ T cells participate in human intestinal acute graft-versus-host disease.JCI insight · 2026Article
- PD-1⁺ CD8⁺ T cells: roles of PD-1 beyond an exhaustion marker.Seminars in immunopathology · 2026Review
- Tumor-draining lymph nodes shape the tumor microenvironment through enrichment of tumor-reactive effector-exhausted CD8Signal transduction and targeted therapy · 2026Article
- BATF3 regulates differentiation of CD8Life science alliance · 2026Article
- Single-cell RNA-sequencing of myasthenia gravis reveals transcriptional heterogeneity and dysfunction of immune cell populations.International immunology · 2026Article
- New insights into progenitor exhausted T cell populations.Nature reviews. Immunology · 2026Article
- Single-cell gain-of-function mapping reveals latent regulatory programs governing CD8Research square · 2026Article
- Systemic pre-conditioning favors effector over exhausted CD8 T-cell subsets following Sup2-IL33 armored CAR T-cell therapy.Journal for immunotherapy of cancer · 2026Article
- Targeting tumor-specific T cells with LAG3-directed interleukin-2 prevents T-cell exhaustion and reinvigorates antitumor immunity.Signal transduction and targeted therapy · 2026Article
123 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
20 authors at 5 institutions in 1 country.
Josephine R GilesDepartment of Systems Pharmacology and Translational Therapeutics, University of Pennsylvania, Philadelphia, PA, USA.
Shin Foong NgiowDepartment of Systems Pharmacology and Translational Therapeutics, University of Pennsylvania, Philadelphia, PA, USA.
Sasikanth ManneDepartment of Systems Pharmacology and Translational Therapeutics, University of Pennsylvania, Philadelphia, PA, USA.
Amy E BaxterDepartment of Systems Pharmacology and Translational Therapeutics, University of Pennsylvania, Philadelphia, PA, USA.ORCID http://orcid.org/0000-0002-1555-0713
Omar KhanDepartment of Systems Pharmacology and Translational Therapeutics, University of Pennsylvania, Philadelphia, PA, USA.
Ping WangDepartment of Systems Pharmacology and Translational Therapeutics, University of Pennsylvania, Philadelphia, PA, USA.
Ryan StaupeDepartment of Systems Pharmacology and Translational Therapeutics, University of Pennsylvania, Philadelphia, PA, USA.
Mohamed S Abdel-HakeemDepartment of Systems Pharmacology and Translational Therapeutics, University of Pennsylvania, Philadelphia, PA, USA.ORCID http://orcid.org/0000-0003-0226-3464
Hua HuangDepartment of Systems Pharmacology and Translational Therapeutics, University of Pennsylvania, Philadelphia, PA, USA.
Divij MathewDepartment of Systems Pharmacology and Translational Therapeutics, University of Pennsylvania, Philadelphia, PA, USA.
Mark M PainterDepartment of Systems Pharmacology and Translational Therapeutics, University of Pennsylvania, Philadelphia, PA, USA.ORCID http://orcid.org/0000-0002-0180-2748
Jennifer E WuDepartment of Systems Pharmacology and Translational Therapeutics, University of Pennsylvania, Philadelphia, PA, USA.
Yinghui Jane HuangDepartment of Systems Pharmacology and Translational Therapeutics, University of Pennsylvania, Philadelphia, PA, USA.ORCID http://orcid.org/0000-0003-0974-9539
Rishi R GoelDepartment of Systems Pharmacology and Translational Therapeutics, University of Pennsylvania, Philadelphia, PA, USA.
Patrick K YanDepartment of Systems Pharmacology and Translational Therapeutics, University of Pennsylvania, Philadelphia, PA, USA.
Giorgos C KarakousisDepartment of Surgery, University of Pennsylvania, Philadelphia, PA, USA.
Xiaowei XuDepartment of Surgery, University of Pennsylvania, Philadelphia, PA, USA.
Tara C MitchellDepartment of Pathology and Laboratory Medicine, University of Pennsylvania, Philadelphia, PA, USA.ORCID http://orcid.org/0000-0002-8186-7284
Alexander C HuangInstitute for Immunology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.ORCID http://orcid.org/0000-0002-0099-0492
E John WherryDepartment of Systems Pharmacology and Translational Therapeutics, University of Pennsylvania, Philadelphia, PA, USA. wherry@pennmedicine.upenn.edu.ORCID http://orcid.org/0000-0003-0477-1956
Translational Therapeutics (United States) · USParker Institute for Cancer Immunotherapy · USUniversity of Pennsylvania · USEmory University · USMerck & Co., Inc., Rahway, NJ, USA (United States) · US
Funding
Virology CoreU19AI082630 · NIAID · MASSACHUSETTS GENERAL HOSPITAL · PI RAYMOND T CHUNG, GEORG Michael LAUER · 2009 to 2026
$48.1MSynergies among inhibitory receptors in tolerance, cancer & antiviral immunityP01AI108545 · NIAID · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI Dario AA Vignali · 2015 to 2026
$30.8MIMMUNOBIOLOGY OF NORMAL AND NEOPLASTIC LYMPHOCYTEST32CA009140 · NCI · UNIVERSITY OF PENNSYLVANIA · PI Malay Haldar, WARREN S PEAR · 1985 to 2026
$16.1MModeling HIV CAR-T cell trafficking and persistence in Non-Human PrimatesU19AI149680 · NIAID · UNIVERSITY OF PENNSYLVANIA · PI RILEY, JAMES L. · 2020 to 2024
$13.2MSequencing and Viral Evolution CoreU19AI117950 · NIAID · UNIVERSITY OF PENNSYLVANIA · PI WHERRY, E. JOHN · 2015 to 2019
$12.0MRadiation and checkpoint blockade for cancer immune therapyP01CA210944 · NCI · UNIVERSITY OF PENNSYLVANIA · PI MAITY, AMIT, MINN, ANDY J · 2017 to 2022
$11.5MTargeting exosomal PDL1 to improve immunotherapyP50CA261608 · NCI · WISTAR INSTITUTE · PI HERLYN, MEENHARD F · 2021 to 2025
$11.3MTargeted Combination Therapy for MelanomaP50CA174523 · NCI · WISTAR INSTITUTE · PI HERLYN, MEENHARD F · 2014 to 2018
$11.1MTemporal control of differentiation and epigenetics of Exhausted CD8 T cells by ToxR01AI155577 · NIAID · UNIVERSITY OF PENNSYLVANIA · PI WHERRY, E. JOHN · 2020 to 2024
$2.7MDissecting transcriptomics and epigenomic signatures of immune cells in type 1 diabetesU01DK127768 · NIDDK · UNIVERSITY OF PENNSYLVANIA · PI VAHEDI, GOLNAZ, WHERRY, E. JOHN · 2020 to 2023
$2.0MRole of tumor burden in limiting durable reinvigoration by PD-1 blockadeK08CA230157 · NCI · UNIVERSITY OF PENNSYLVANIA · PI HUANG, ALEXANDER · 2019 to 2023
$1.0MThe Role of Tox in Regulating T Cell ExhaustionF30AI129263 · NIAID · UNIVERSITY OF PENNSYLVANIA · PI KHAN, OMAR · 2017 to 2019
$90kNCI NIH HHS K08 CA230157NCI NIH HHS P01 CA210944NCI NIH HHS P50 CA174523NCI NIH HHS P50 CA261608NCI NIH HHS T32 CA009140NIAID NIH HHS F30 AI129263NIAID NIH HHS P01 AI108545NIAID NIH HHS R01 AI155577NIAID NIH HHS U19 AI082630NIAID NIH HHS U19 AI117950NIAID NIH HHS U19 AI149680NIDDK NIH HHS U01 DK127768
Abstract
Naïve CD8
Indexed as
CD8-Positive T-LymphocytesLymphocytic ChoriomeningitisChromatinEpigenesis, GeneticHumansLymphocytic choriomeningitis virusTranscriptomeChromatin
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.